Laura C. Schell

Array ( [id] => 16177234 [patent_doc_number] => 20200224202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of CD39 [patent_app_type] => utility [patent_app_number] => 16/340259 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18412068 [patent_doc_number] => 11666595 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer [patent_app_type] => utility [patent_app_number] => 16/340318 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 10 [patent_no_of_words] => 11517 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641946 [patent_doc_number] => 20180105813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => Treatment of Cancers with Micro-RNA Inhibitors [patent_app_type] => utility [patent_app_number] => 15/724860 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15724860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682459 [patent_doc_number] => 20190240344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => FUNCTIONAL RNA AND SMALL-MOLECULE DRUG THERAPEUTIC COMPLEXES AND NANOPARTICLE DELIVERY VEHICLES [patent_app_type] => utility [patent_app_number] => 16/338909 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432357 [patent_doc_number] => 20200030361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES [patent_app_type] => utility [patent_app_number] => 16/335663 [patent_app_country] => US [patent_app_date] => 2017-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833541 [patent_doc_number] => 20190275171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => GENE THERAPY AND TARGETED DELIVERY OF CONJUGATED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/335171 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251631 [patent_doc_number] => 10138497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Agents for improved delivery of nucleic acids to eukaryotic cells [patent_app_type] => utility [patent_app_number] => 15/707740 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9791 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15707740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14058331 [patent_doc_number] => 10233449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-19 [patent_title] => Methods and compositions for selecting siRNA of improved functionality [patent_app_type] => utility [patent_app_number] => 15/705650 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 31368 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14653391 [patent_doc_number] => 20190233824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => PD-1 SPECIFIC APTAMERS [patent_app_type] => utility [patent_app_number] => 16/330813 [patent_app_country] => US [patent_app_date] => 2017-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885509 [patent_doc_number] => 10195286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Compounds and methods for trans-membrane delivery of molecules [patent_app_type] => utility [patent_app_number] => 15/691821 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 23113 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15691821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13805151 [patent_doc_number] => 10179837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-15 [patent_title] => Dendronized polymers for nucleic acid delivery [patent_app_type] => utility [patent_app_number] => 15/688718 [patent_app_country] => US [patent_app_date] => 2017-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 25 [patent_no_of_words] => 15259 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15688718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534467 [patent_doc_number] => 20190202855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => POLYNUCLEOTIDE CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/326542 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092801 [patent_doc_number] => 20170349895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'NUCLEASE-RESISTANT DNA ANALOGUES' [patent_app_type] => utility [patent_app_number] => 15/678551 [patent_app_country] => US [patent_app_date] => 2017-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8477 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15678551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083419 [patent_doc_number] => 20190336520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => USE OF A SIRNA FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/345586 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988851 [patent_doc_number] => 20220354888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS [patent_app_type] => utility [patent_app_number] => 16/322000 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342915 [patent_doc_number] => 20190153430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => METHOD FOR GENOME EDITING [patent_app_type] => utility [patent_app_number] => 16/322924 [patent_app_country] => US [patent_app_date] => 2017-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436169 [patent_doc_number] => 20200032268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 16/321229 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18201191 [patent_doc_number] => 11583562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Viral vectors for treating Parkinson's disease [patent_app_type] => utility [patent_app_number] => 16/318345 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 12354 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318345 [rel_patent_id] =>[rel_patent_doc_number] =>)